Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) and Gossamer Bio (NASDAQ:GOSS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
Institutional and Insider Ownership
81.2% of Gossamer Bio shares are owned by institutional investors. 69.3% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Actuate Therapeutics has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Actuate Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
| Gossamer Bio | 2 | 3 | 5 | 0 | 2.30 |
Actuate Therapeutics presently has a consensus price target of $20.33, indicating a potential upside of 591.61%. Gossamer Bio has a consensus price target of $5.43, indicating a potential upside of 869.39%. Given Gossamer Bio’s higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Actuate Therapeutics.
Earnings & Valuation
This table compares Actuate Therapeutics and Gossamer Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Actuate Therapeutics | N/A | N/A | -$27.28 million | ($0.87) | -3.38 |
| Gossamer Bio | $114.70 million | 1.13 | -$56.53 million | ($0.69) | -0.81 |
Actuate Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Actuate Therapeutics and Gossamer Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Actuate Therapeutics | N/A | -2,925.12% | -250.69% |
| Gossamer Bio | -354.50% | -1,774.72% | -59.74% |
Summary
Gossamer Bio beats Actuate Therapeutics on 9 of the 13 factors compared between the two stocks.
About Actuate Therapeutics
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
About Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
